Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the first quarter ended March 31, 2014 and provided an update on recent corporate events.
“The final results from the GALAXY-1 study in non-small cell lung adenocarcinoma represent a significant addition to the collection of encouraging data that our ganetespib development program has generated in multiple cancer indications and confirms the choice of the chemo-sensitive patient population for the GALAXY-2 Phase 3 trial,” said Keith Gollust, Chairman of the Executive Committee of Synta.
Help employers find you! Check out all the jobs and post your resume.
